142 related articles for article (PubMed ID: 26204212)
1. Correlation of SUV-Derived Indices With Tumoral Aggressiveness of Gliomas in Static 18F-FDOPA PET: Use in Clinical Practice.
Janvier L; Olivier P; Blonski M; Morel O; Vignaud JM; Karcher G; Taillandier L; Verger A
Clin Nucl Med; 2015 Sep; 40(9):e429-35. PubMed ID: 26204212
[TBL] [Abstract][Full Text] [Related]
2. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
[TBL] [Abstract][Full Text] [Related]
3.
Patel CB; Fazzari E; Chakhoyan A; Yao J; Raymond C; Nguyen H; Manoukian J; Nguyen N; Pope W; Cloughesy TF; Nghiemphu PL; Czernin J; Lai A; Ellingson BM
J Neurooncol; 2018 Sep; 139(2):399-409. PubMed ID: 29679199
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
[TBL] [Abstract][Full Text] [Related]
5. IDH mutation is paradoxically associated with higher
Verger A; Metellus P; Sala Q; Colin C; Bialecki E; Taieb D; Chinot O; Figarella-Branger D; Guedj E
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1306-1311. PubMed ID: 28293705
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of quantitative criteria for glioma grading with static and dynamic 18F-FDopa PET/CT.
Nioche C; Soret M; Gontier E; Lahutte M; Dutertre G; Dulou R; Capelle L; Guillevin R; Foehrenbach H; Buvat I
Clin Nucl Med; 2013 Feb; 38(2):81-7. PubMed ID: 23334119
[TBL] [Abstract][Full Text] [Related]
7.
Renard D; Collombier L; Laurent-Chabalier S; Mura T; Le Floch A; Fertit HE; Thouvenot E; Guillamo JS
J Neurol; 2021 Apr; 268(4):1266-1275. PubMed ID: 33084938
[TBL] [Abstract][Full Text] [Related]
8. FDOPA PET-CT of Nonenhancing Brain Tumors.
Bund C; Heimburger C; Imperiale A; Lhermitte B; Chenard MP; Lefebvre F; Kremer S; Proust F; Namer IJ
Clin Nucl Med; 2017 Apr; 42(4):250-257. PubMed ID: 28114224
[TBL] [Abstract][Full Text] [Related]
9. A high
Isal S; Gauchotte G; Rech F; Blonski M; Planel S; Chawki MB; Karcher G; Marie PY; Taillandier L; Verger A
Br J Radiol; 2018 Apr; 91(1084):20170803. PubMed ID: 29271237
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric evaluation of low grade gliomas at follow-up: comparison between diffusion and perfusion MR with (18)F-FDOPA PET.
Rossi Espagnet MC; Romano A; Mancuso V; Cicone F; Napolitano A; Scaringi C; Minniti G; Bozzao A
Br J Radiol; 2016 Oct; 89(1066):20160476. PubMed ID: 27505026
[TBL] [Abstract][Full Text] [Related]
11. Repeatability of
Lodge MA; Holdhoff M; Leal JP; Bag AK; Nabors LB; Mintz A; Lesser GJ; Mankoff DA; Desai AS; Mountz JM; Lieberman FS; Fisher JD; Desideri S; Ye X; Grossman SA; Schiff D; Wahl RL
J Nucl Med; 2017 Mar; 58(3):393-398. PubMed ID: 27688473
[TBL] [Abstract][Full Text] [Related]
12. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
[TBL] [Abstract][Full Text] [Related]
13. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy.
Calcagni ML; Galli G; Giordano A; Taralli S; Anile C; Niesen A; Baum RP
Clin Nucl Med; 2011 Oct; 36(10):841-7. PubMed ID: 21892031
[TBL] [Abstract][Full Text] [Related]
14. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study.
Pafundi DH; Laack NN; Youland RS; Parney IF; Lowe VJ; Giannini C; Kemp BJ; Grams MP; Morris JM; Hoover JM; Hu LS; Sarkaria JN; Brinkmann DH
Neuro Oncol; 2013 Aug; 15(8):1058-67. PubMed ID: 23460322
[TBL] [Abstract][Full Text] [Related]
15. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
16. Can (18)F-FDOPA PET/CT predict survival in patients with suspected recurrent glioma? A prospective study.
Karunanithi S; Sharma P; Kumar A; Gupta DK; Khangembam BC; Ballal S; Kumar R; Kumar R; Bal C
Eur J Radiol; 2014 Jan; 83(1):219-25. PubMed ID: 24191944
[TBL] [Abstract][Full Text] [Related]
17. Differentiating high-grade glioma progression from treatment-related changes with dynamic [
Rozenblum L; Zaragori T; Tran S; Morales-Martinez A; Taillandier L; Blonski M; Rech F; Galanaud D; Kas A; Verger A
Eur Radiol; 2023 Apr; 33(4):2548-2560. PubMed ID: 36367578
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and grading accuracy of
Xiao J; Jin Y; Nie J; Chen F; Ma X
BMC Cancer; 2019 Aug; 19(1):767. PubMed ID: 31382920
[TBL] [Abstract][Full Text] [Related]
19. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
Kosztyla R; Chan EK; Hsu F; Wilson D; Ma R; Cheung A; Zhang S; Moiseenko V; Benard F; Nichol A
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1100-6. PubMed ID: 24161427
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
